Emollient creams and ointments, hydrogenated castor oil-containing
Brand names: various
These are leave-on emollient creams and ointments containing hydrogenated castor oil, used to moisturise dry, scaly skin conditions such as eczema and ichthyosis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Hydrogenated castor oil acts as an occlusive and emollient lipid that coats the skin, reducing transepidermal water loss and helping repair the skin barrier.
Prescribing in practice
- Paraffin and oil-based emollients leave a flammable residue on clothing, bedding and dressings, so patients must be warned to keep away from naked flames and not to smoke.
- Occasional contact irritation or sensitisation can occur, so review if the skin worsens with use.
- Apply liberally and frequently as a leave-on emollient to maintain skin hydration.
Monitoring
No laboratory monitoring is required; review skin condition, tolerability and adherence to fire-safety advice at follow-up.
Counselling the patient
- Apply generously and often, smoothing in the direction of hair growth.
- Avoid naked flames and smoking, as the product on skin and fabrics is flammable.
- Report any increase in redness or irritation.
Evidence & guidelines
Emollients are a mainstay of managing dry skin and eczema in NICE guidance, and the MHRA has highlighted the fire risk associated with emollient residues on fabric.
Reference: NICE CKS Eczema; BAD; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- HE-MACS (History and ECG-Based Manchester ACS Risk Score) · ACS Risk Stratification
- Weight-Based Levothyroxine Dose Calculator · Thyroid
- Number Needed to Treat (NNT) / Number Needed to Harm (NNH) · Evidence-Based Medicine
- HIV Opportunistic Infection Risk (CD4-Based) · HIV / Immunodeficiency
- Estimated Bladder Capacity (Age-based) · Urodynamics
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD